Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

98.16 +0.18 (+0.18%)
Streaming Delayed Price Updated: 11:10 AM EDT, Jun 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 107,004
Open 97.64
Bid (Size) 98.08 (2)
Ask (Size) 98.24 (2)
Prev. Close 97.98
Today's Range 97.11 - 98.48
52wk Range 85.21 - 125.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating BioNTech: Insights From 15 Financial Analysts
Via Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety

Performance

YTD
-12.63%
-12.63%
1 Month
+5.87%
+5.87%
3 Month
+1.93%
+1.93%
6 Month
-2.32%
-2.32%
1 Year
-13.13%
-13.13%

More News

Read More
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
Via Benzinga
What's Going On With Novavax Stock?
Via Benzinga
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Exposures COVID-19
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
Via Benzinga
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Via Benzinga
Why Vaccine Stocks Rallied This Week
Via The Motley Fool
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Via Benzinga
Exposures COVID-19
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
3 Blue-Chip Stocks Set to Triple Soon
Via InvestorPlace
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Via Benzinga
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.